Delayed activation of caspase-independent apoptosis during heart failure in transgenic mice overexpressing caspase inhibitor CrmA
- 1 November 2010
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 299 (5), H1374-H1381
- https://doi.org/10.1152/ajpheart.00168.2010
Abstract
Although caspase activation is generally thought to be necessary to induce apoptosis, recent evidence suggests that apoptosis can be activated in the setting of caspase inhibition. In this study, we tested the hypothesis that caspase-independent apoptotic pathways contribute to the development of heart failure in the absence of caspase activation. Acute cardiomyopathy was induced using a single dose of doxorubicin (Dox, 20 mg/kg) injected into male wild-type (WT) and transgenic (Tg) mice with a cardiac-specific expression of cytokine response modifier A (CrmA), a known caspase inhibitor. Early (6 day) survival was significantly better in CrmA Tg (81%) than WT (38%) mice. Twelve days after Dox injection, however, the mortality benefit had dissipated, and increased cardiac apoptosis was observed in both groups. There was, however, a significantly greater release of apoptosis-inducing factor (AIF) from mitochondria to cytosol in CrmA Tg compared with WT mice, which suggests that an enhancement of activation in caspase-independent apoptotic pathways had occurred. The administration of a poly(ADP-ribose) polymerase-1 inhibitor, 4-amino-1,8-naphthalimide (4-AN), to Dox-treated mice resulted in significantly improved cardiac function, a significant blockade of AIF released from mitochondria, and decreased cardiac apoptosis. There were also significantly improved survival in WT (18% without 4-AN vs. 89% with 4-AN) and CrmA Tg (13% without 4-AN vs. 93% with 4-AN) mice 12 days after Dox injection. In conclusion, these findings suggest that apoptosis can be induced in the heart lacking caspase activation via caspase-independent pathways and that enabling the inhibition of AIF activation may provide a significant cardiac benefit.This publication has 41 references indexed in Scilit:
- Role of AIF in cardiac apoptosis in hypertrophic cardiomyocytes from Dahl salt-sensitive ratsCardiovascular Research, 2009
- Measurement of cardiac function using pressure–volume conductance catheter technique in mice and ratsNature Protocols, 2008
- Role of caspase-independent apoptosis in cardiovascular diseasesFrontiers in Bioscience-Landmark, 2008
- The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathyJCI Insight, 2007
- Pharmacological Inhibition of CB1Cannabinoid Receptor Protects Against Doxorubicin-Induced CardiotoxicityJournal of the American College of Cardiology, 2007
- Response of caspase-independent apoptotic factors to high salt diet-induced heart failureJournal of Molecular and Cellular Cardiology, 2007
- Switch from Caspase-dependent to Caspase-independent Death during Heart DevelopmentOnline Journal of Public Health Informatics, 2006
- Poly(ADP-Ribose) Polymerase Promotes Cardiac Remodeling, Contractile Failure, and Translocation of Apoptosis-Inducing Factor in a Murine Experimental Model of Aortic Banding and Heart FailureThe Journal of pharmacology and experimental therapeutics, 2004
- Mitochondrial-to-nuclear translocation of apoptosis-inducing factor in cardiac myocytes during oxidant stress: potential role of poly(ADP-ribose) polymerase-1Cardiovascular Research, 2004
- Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatmentOncogene, 2002